Pain Management for Polymyalgia Rheumatica
Glucocorticoids are the primary treatment for polymyalgia rheumatica, with an initial dose of 12.5-25 mg prednisone equivalent daily, NOT NSAIDs or analgesics alone. 1
Initial Treatment Strategy
Start with oral prednisone 12.5-25 mg daily as a single morning dose. 1 The specific dose within this range depends on:
Use 20-25 mg daily if the patient has high ESR (>40 mm/hr), peripheral inflammatory arthritis, or female sex (all associated with higher relapse risk) AND lacks significant comorbidities 1
Use 12.5-15 mg daily if the patient has diabetes, osteoporosis, glaucoma, cardiovascular disease, or other glucocorticoid-sensitive comorbidities 1
Never use initial doses ≤7.5 mg/day (conditionally discouraged) or >30 mg/day (strongly contraindicated—consider alternative diagnoses if higher doses seem necessary) 1
Clinical improvement should occur within 2 weeks; almost complete response is expected within 4 weeks. 1 If inadequate response occurs, increase the dose up to 25 mg prednisone equivalent and reconsider the diagnosis. 1
Glucocorticoid Tapering Protocol
Taper to 10 mg/day within 4-8 weeks after achieving initial response. 1
Once remission is achieved, reduce by 1 mg every 4 weeks (or use alternate-day schedules like 10/7.5 mg if 1 mg tablets unavailable) until complete discontinuation. 1
For relapses: increase back to the pre-relapse dose, then taper gradually over 4-8 weeks to the dose where relapse occurred. 1
Alternative Glucocorticoid Formulations
Intramuscular methylprednisolone 120 mg every 3 weeks can be used as an alternative to oral glucocorticoids, with potential benefits of lower cumulative doses and less weight gain. 1 This option is particularly useful for patients with adherence issues or gastrointestinal intolerance. 1
Use single daily doses, not divided doses, except when prominent night pain occurs during tapering below 5 mg/day prednisone equivalent. 1
Glucocorticoid-Sparing Agents
Methotrexate
Consider adding methotrexate 7.5-10 mg/week (or up to 25 mg/week based on recent evidence) early in treatment for patients with: 1, 2
- High risk of relapse (female sex, high ESR >40, peripheral arthritis)
- Significant comorbidities where prolonged glucocorticoid use is particularly hazardous
- Previous relapse or glucocorticoid-related adverse events
A 2025 high-quality RCT demonstrated that methotrexate 25 mg/week significantly increased GC-free remission rates (80% vs 46% placebo) at 52 weeks in newly diagnosed PMR. 2 This represents the strongest recent evidence for early methotrexate introduction.
IL-6 Receptor Inhibitors
Tocilizumab and sarilumab are highly effective glucocorticoid-sparing agents with consistent evidence from multiple low risk-of-bias trials showing higher remission rates and reduced glucocorticoid burden. 3, 4, 5 Consider these biologics for:
- Patients with frequent relapses despite methotrexate
- Those experiencing significant glucocorticoid toxicity
- Patients unable to taper below moderate glucocorticoid doses
Agents to Avoid
TNF-α blocking agents are strongly contraindicated—they are ineffective for PMR treatment. 1
Chinese herbal preparations (Yanghe and Biqi capsules) are strongly contraindicated. 1
NSAIDs and Analgesics
NSAIDs should NOT be used as primary treatment for PMR. 1 They may only be considered short-term for pain related to other coexisting conditions (e.g., osteoarthritis), not for PMR inflammation itself. 1
No specific recommendations exist for analgesics as primary PMR treatment. 1
Monitoring and Follow-Up
Follow patients every 4-8 weeks in the first year, every 8-12 weeks in the second year, and as needed for relapses or during tapering. 1
Monitor disease activity, inflammatory markers (ESR/CRP), glucocorticoid-related adverse events, and comorbidities at each visit. 1
Adjunctive Measures
Implement an individualized exercise program to maintain muscle mass and function and reduce fall risk, especially critical in older patients on long-term glucocorticoids. 1
Ensure osteoporosis prophylaxis (calcium, vitamin D, bisphosphonates as indicated) given the prolonged glucocorticoid exposure. 1
Common Pitfalls
- Starting with doses >30 mg/day suggests an alternative diagnosis and warrants specialist referral 1
- Using NSAIDs as monotherapy delays appropriate treatment and allows disease progression 1
- Tapering too rapidly increases relapse risk, but evidence suggests faster tapering may not necessarily compromise outcomes compared to prolonged protocols 6
- Failing to assess and address glucocorticoid-related comorbidities before initiating treatment 1